Progentec Diagnostics, Inc.
By launching first-in-market biomarker tests and developing digital biomarkers for the continuous monitoring of disease, we support clinicians in their effort to provide exceptional care. Our technologies will empower clinician decision making and ensure that patients are able to be active participants in their care. Measuring multiple sclerosis disease activity with a blood test. Tracking multiple sclerosis disease progression with remotely-administered cognitive tests. The company is collaborating with a number of research institutions and individuals around the world engaged in bringing the latest technological innovations to the field of diagnostics.
Company details
Find locations served, office locations
- Business Type:
- Software vendor
- Industry Type:
- Medical Monitoring
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
Why We Do What We Do
25 Million Americans with autoimmune diseases demand a change to the status quo
Research and science do not progress uniformly. The last 60 years have brought advancements and the adoption of new technologies. However, this development has been siloed in high-prevalence conditions, like type II diabetes. As a result, misunderstood diseases like lupus and multiple sclerosis have begun taking their toll.
Lupus is now the 10th leading cause of death for women ages 15-24. And, only one new lupus medication has been approved by the FDA in the last 60 years.
By launching first-in-market biomarker tests and developing digital biomarkers for the continuous monitoring of disease, we support clinicians in their effort to provide exceptional care. Our technologies will empower clinician decision making and ensure that patients are able to be active participants in their care.
Vision
Improve health outcomes with data-driven, proactive healthcare
Proactive interventions will make life better for people with autoimmune diseases. When clinicians have actionable data, they can work with patients to strategically adjust treatment plans in order to:
- Limit irreversible organ damage
- Reduce the severity of flares and symptoms
- Personalize care to the desires and needs of the patient
This type of care encourages touchpoints with clinicians and analyzing complex data to identify early risk indicators. As a result, more patient care episodes will occur at the patient's home and in outpatient clinics. Best of all, patients will love the support they receive.
Mission
Develop diagnostic & care solutions used in the detection and treatment of autoimmune diseases
Progentec will bring about significant improvements that are clinically meaningful to existing diagnostic solutions in the market. We’re focused on providing answers to basic questions, which have the potential to make a big impact on current treatment paradigms – thus helping healthcare professionals and patients improve outcomes at reduced costs.
Company Initiative
- Unlock laboratory services and scientific research that enable clinicians to improve patient care and outcomes
- Evaluate disease-specific biomarkers and diagnostic products
- Leverage scientific analysis relating to pharmaceutical, medical device, and diagnostic development
- Cultivate relationships within the scientific community
- Transform clinical research by conducting remote clinical studies
- Deliver disease-specific, personalized interventions to measurably improve outcomes
- Integrate sensor and ePRO data to make remote patient monitoring easy for patients and useful for clinicians
- It starts with creating value. Build patient-centric technologies that solve problems and answer questions
- Ask the patient community! Listen to the responses and make sure those insights are reflected in what we do
- Bring people into our world by listening to theirs
Clinical Research
The study entitled Translation of a Diagnostic Test for Lupus Flare Prediction from Bench to Clinic (TOTAL FEEDBACK) is investigating the presence of certain blood proteins before and after a lupus flare has occurred.
One of the hallmarks of systemic lupus erythematosus (SLE) is periodic ‘flares,’ a period of increased disease activity, which can lead to a reduced quality of life or even hospitalization.
Progentec recruited patients at several locations across the United States. We are working with both patients and rheumatologists to evaluate and study patient’s bloodwork over the span of six months. The findings of TOTAL FEEDBACK will directly aid in the development of future technologies.
Continuing Progentec’s predictive research, our team has partnered with two Lupus Centers of Excellence in the United States: the Mayo Clinic and the Oklahmoa Medical Research Foundation. Patients at both locations were recruited to participate in this study with the goal of supporting the development and refinement of technologies to support the care of people with lupus.